Recent blog posts
Incyte Announces Acquisition of Escient Pharmaceuticals, Expanding First-in-Class Drug Pipeline Focused on MRGPRX2/MRGPRX4
Hot Spotlight
5 min read
Incyte Announces Acquisition of Escient Pharmaceuticals, Expanding First-in-Class Drug Pipeline Focused on MRGPRX2/MRGPRX4
20 May 2024
On April 23, global biopharmaceutical company Incyte announced the finalization of an agreement to fully acquire clinical-stage drug development company Escient Pharmaceuticals.
Read →
Novartis continues to increase its investments in the "cyclic peptide + radiopharmaceuticals" therapeutic field
Hot Spotlight
5 min read
Novartis continues to increase its investments in the "cyclic peptide + radiopharmaceuticals" therapeutic field
11 May 2024
This acquisition will not only enrich Novartis's research and development pipeline in Radioligand Therapy (RLT) but will also enhance the company’s research foundation and clinical supply capabilities in oncology and RLT platform innovations.
Read →
What ADC-related progress will CStone Pharmaceuticals reveal at the ASCO conference?
Hot Spotlight
2 min read
What ADC-related progress will CStone Pharmaceuticals reveal at the ASCO conference?
11 May 2024
The disclosed CS5001 is an ADC targeting ROR1, featuring a unique design.
Read →
What ADC-related progress will Keymed Biosciences reveal at the ASCO conference?
Hot Spotlight
3 min read
What ADC-related progress will Keymed Biosciences reveal at the ASCO conference?
11 May 2024
CMG901 (AZD0901) is a potentially first-in-class antibody-drug conjugate targeting Claudin 18.2, conjugated with monomethyl auristatin E (MMAE) as the payload.
Read →
What ADC-related progress will Mabwell (Shanghai) Bioscience reveal at the ASCO conference?
Hot Spotlight
7 min read
What ADC-related progress will Mabwell (Shanghai) Bioscience reveal at the ASCO conference?
10 May 2024
At the upcoming ASCO conference, Mabwell (Shanghai) Bioscience will present the Phase I/II clinical study results of 9MW2821 for several advanced solid tumors through an oral report.
Read →
What ADC-related progress will Alphamab Biopharmaceuticals reveal at the ASCO conference?
Hot Spotlight
3 min read
What ADC-related progress will Alphamab Biopharmaceuticals reveal at the ASCO conference?
10 May 2024
JSKN003 is a novel ADC targeting two distinct epitopes of HER2, independently developed by Alphamab Biopharmaceuticals utilizing its proprietary glycan-based site-specific conjugation platform.
Read →
What ADC-related progress will Medilink Therapeutics reveal at the ASCO conference?
Hot Spotlight
2 min read
What ADC-related progress will Medilink Therapeutics reveal at the ASCO conference?
10 May 2024
Medilink Therapeutics will present preliminary results from the first human clinical Phase 1 trial of YL202 for the treatment of locally advanced or metastatic non-small cell lung cancer and breast cancer (NCT05653752).
Read →
What ADC-related progress will RemeGen reveal at the ASCO conference?
Hot Spotlight
4 min read
What ADC-related progress will RemeGen reveal at the ASCO conference?
10 May 2024
RemeGen Showcases 16 New Clinical Studies on ADCs Disitamab Vedotin and RC88 Targeting Multiple Cancer Types at Conference.
Read →
What ADC-related progress will Lepu Biopharma reveal at the ASCO conference?
Hot Spotlight
4 min read
What ADC-related progress will Lepu Biopharma reveal at the ASCO conference?
8 May 2024
Lepu Biopharma is an innovative biopharmaceutical company focused on the field of oncology treatment, particularly in targeted therapy and immunotherapy.
Read →
What ADC-related progress will Kelun Botai Biomedicine reveal at the ASCO conference?
Hot Spotlight
4 min read
What ADC-related progress will Kelun Botai Biomedicine reveal at the ASCO conference?
8 May 2024
At the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Kelun Botai Biomedicine will disclose the research progress of SKB264.
Read →
What ADC-related progress will Innovent Biologics reveal at the ASCO conference?
Hot Spotlight
3 min read
What ADC-related progress will Innovent Biologics reveal at the ASCO conference?
7 May 2024
Innovent Biologics will present a poster demonstrating the safety and efficacy of IBI343 in patients with advanced pancreatic ductal adenocarcinoma or cholangiocarcinoma.
Read →
Exploring the Chemical Diversity of Macrocyclic Oligoamides
Hot Spotlight
7 min read
Exploring the Chemical Diversity of Macrocyclic Oligoamides
30 April 2024
This paper reported an innovative computational approach that successfully achieved the design and prediction of macrocyclic oligoamides composed of alpha, beta, gamma, and other non-natural amino acid backbone chemical structures.
Read →